fbpx

Enterome announces research collaboration with renowned US Cancer Institute focused on new microbiome-derived cancer immunotherapy

New collaboration to evaluate the potential of bacterial antigens that mimic tumor
antigens and neoantigens (“onco-mimics”) to drive immune responses

Paris, France and Cambridge, MA, USA – March 20, 2019
ENTEROME SA, a clinical-stage biopharmaceutical company developing innovative
therapies based on the identification and therapeutic application of bioactive molecules
expressed, secreted and regulated by the gut microbiome, has entered into a research
and development collaboration with Dana-Farber Cancer Institute (Boston, MA) to
evaluate and develop gut microbiome-derived antigens as potential cancer
immunotherapies.

Enterome is developing an innovative cancer immunotherapy, based on the concept of
“molecular mimicry,” whereby microbiome-derived bacterial antigens show molecular
similarity with Tumor-associated Antigens (TAAs) and Tumor-specific Neoantigens (TSNAs).
Based on this similarity, bacterial antigens (“onco-mimics”) would trigger tumor-specific
cytotoxic T cell immune responses.

Enterome has developed a discovery platform to identify such onco-mimics from the
human gut microbiome and has advanced EO2401 as its first clinical candidate. EO2401
comprises several antigenic peptides that mimic antigens on brain tumors and is targeting
first clinical trials in 2019 as a potential new immunotherapy for recurrent glioblastoma
multiforme (GBM) for which no curative treatments exist.

The collaboration brings together Enterome’s ability to identify potential TAAs and TSNAs
as well as to generate bacterial onco-mimics for the selected TAAs and TSNAs with the
complementary translational expertise from the research groups at Dana-Farber Cancer
Institute led by Dr. David Reardon at the Center for Neuro-Oncology and Dr. Paul
Kirschmeier at the Belfer Center for Applied Cancer Science. Drs. Reardon’s and
Kirschner’s groups are focused on driving innovative research programs and clinical trials
to improve cure rates in patients with brain and spinal cancers, with a particular focus on
immunotherapies.

Through this collaboration Enterome will have access to knowledge, scientific expertise
and preclinical models at Dana-Farber Cancer Institute that will support the in vivo
validation and further development of Enterome’s immunotherapy approach for cancer.
“We are delighted to have signed this wide-ranging collaboration with one of the most
esteemed cancer research institutions in the US,” said Pierre Belichard, CEO of Enterome.
“Drs. Reardon and Kirschmeier are accomplished and renowned clinician-scientists in their
respective fields and their groups have pioneered novel approaches to cancer therapy,
particularly in the brain. We believe that this collaboration will be highly productive in
further validating our onco-mimic immunotherapy approach and enable us to develop our
pipeline of new candidates for multiple cancer indications.”

Contacts
Enterome
Pierre Belichard, CEO
Tel. +33 1 75 77 27 87
media@enterome.com
Public Relations
EU: Mark Swallow / Sylvie Berrebi / David Dible
US: Marine Perrier-Barthez
Citigate Dewe Rogerson
Tel. +44 207 638 9571 / +1 424 341 9140
enterome@citigatedewerogerson.com

Investor Relations
Melody Carey
Rx Communications Group
Tel. +1 917 322 2571
mcarey@rxir.com

About Enterome
Enterome is a clinical-stage biopharmaceutical company leveraging its unique
knowledge of the key functional and molecular interactions between the gut microbiome
and the human body to develop targeted therapeutics.
Enterome is advancing a pipeline of small molecule and peptide candidates to treat
microbiome-associated diseases with a focus on cancer and auto-immune disease: these
include EB8018, a selective FimH blocker, in a Phase 1b clinical trial for Crohn’s disease
(partnered with Takeda); and EO2401, an innovative microbiome-derived cancer
immunotherapy (“onco-mimic”), which is expected to enter clinical trial in glioblastoma
multiforme (GBM) patients in 2019.
The Company’s strategic drug discovery is driven by its proprietary platform enabling the
identification and therapeutic application of the bioactive molecules that are expressed,
secreted and regulated by the gut microbiome.
Enterome’s partners include Takeda, Bristol-Myers Squibb and Janssen Biotech.
The Company is backed by leading venture capital investors (Seventure Partners,
Lundbeckfonden Ventures, Health for Life Capital, Omnes Capital and Principia) and
strategic investors (BMS, Nestlé Health Science, Shire and INRA Transfert).
Additional information about Enterome is available at: www.enterome.com
Follow us on Twitter: @EnteromeSA

Related Posts

Nyheder

BONESUPPORT HOLDING AB (publ) announces that the patient enrolment schedule for the ongoing FORTIFY study is extended
21. august 2019
Lundbeckfonden udvider ledelsen med to stærke profiler
8. august 2019
Event: Fra trip til koma – bliv klogere på din bevidsthed
6. august 2019

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge